GALAPAGOS NV-SPON ADR (GLPG) Stock Price, Quote, News and Overview
NASDAQ:GLPG - Nasdaq - US36315X1019 - ADR - Currency: USD
GLPG Quote, Performance and Key Statistics
26.74
+0.01 (+0.04%)
The current stock price of GLPG is 26.74 USD. In the past month the price increased by 12.64%. In the past year, price decreased by -26.21%.
GLPG Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About GLPG
Company Profile
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. The company is headquartered in Malines (Mechelen), Antwerpen and currently employs 646 full-time employees. The company went IPO on 2005-05-06. The firm is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The firm focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. The company develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. The company discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The firm acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.
Company Info
GALAPAGOS NV-SPON ADR
Generaal De Wittelaan L11 A3
MALINES (MECHELEN) ANTWERPEN 2800 BE
CEO: Onnovan deStolpe
Employees: 683
Company Website: https://www.glpg.com/
Investor Relations: https://www.glpg.com/investor-center
Phone: 3215342900
GALAPAGOS NV-SPON ADR / GLPG FAQ
What is the stock price of GALAPAGOS NV-SPON ADR today?
The current stock price of GLPG is 26.74 USD. The price increased by 0.04% in the last trading session.
What is the ticker symbol for GALAPAGOS NV-SPON ADR stock?
The exchange symbol of GALAPAGOS NV-SPON ADR is GLPG and it is listed on the Nasdaq exchange.
On which exchange is GLPG stock listed?
GLPG stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for GALAPAGOS NV-SPON ADR stock?
20 analysts have analysed GLPG and the average price target is 34.7 USD. This implies a price increase of 29.75% is expected in the next year compared to the current price of 26.74. Check the GALAPAGOS NV-SPON ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is GALAPAGOS NV-SPON ADR worth?
GALAPAGOS NV-SPON ADR (GLPG) has a market capitalization of 1.76B USD. This makes GLPG a Small Cap stock.
How many employees does GALAPAGOS NV-SPON ADR have?
GALAPAGOS NV-SPON ADR (GLPG) currently has 683 employees.
What are the support and resistance levels for GALAPAGOS NV-SPON ADR (GLPG) stock?
GALAPAGOS NV-SPON ADR (GLPG) has a support level at 26.73 and a resistance level at 27.51. Check the full technical report for a detailed analysis of GLPG support and resistance levels.
Is GALAPAGOS NV-SPON ADR (GLPG) expected to grow?
The Revenue of GALAPAGOS NV-SPON ADR (GLPG) is expected to decline by -46.03% in the next year. Check the estimates tab for more information on the GLPG EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy GALAPAGOS NV-SPON ADR (GLPG) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GLPG, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GLPG, evaluating the profitability, health, valuation and growth aspects
- GALAPAGOS NV-SPON ADR (GLPG) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- GALAPAGOS NV-SPON ADR (GLPG) Sales and EPS estimates to see what analysts future expectations are.
- GALAPAGOS NV-SPON ADR (GLPG) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- GALAPAGOS NV-SPON ADR (GLPG) Insider and Institutional Ownership to learn about the owners and their transactions.
- GALAPAGOS NV-SPON ADR (GLPG) Stock Chart to make your own analysis
- GALAPAGOS NV-SPON ADR (GLPG) Latest news and press-releases to stay up to date.
Does GALAPAGOS NV-SPON ADR (GLPG) stock pay dividends?
GLPG does not pay a dividend.
When does GALAPAGOS NV-SPON ADR (GLPG) report earnings?
GALAPAGOS NV-SPON ADR (GLPG) will report earnings on 2025-04-23.
What is the Price/Earnings (PE) ratio of GALAPAGOS NV-SPON ADR (GLPG)?
The PE ratio for GALAPAGOS NV-SPON ADR (GLPG) is 8.1. This is based on the reported non-GAAP earnings per share of 3.3 and the current share price of 26.74 USD. Check the full fundamental report for a full analysis of the valuation metrics for GLPG.
What is the Short Interest ratio of GALAPAGOS NV-SPON ADR (GLPG) stock?
The outstanding short interest for GALAPAGOS NV-SPON ADR (GLPG) is 3.48% of its float. Check the ownership tab for more information on the GLPG short interest.
GLPG Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to GLPG. When comparing the yearly performance of all stocks, GLPG is a bad performer in the overall market: 80.47% of all stocks are doing better.
GLPG Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to GLPG. While GLPG seems to be doing ok healthwise, there are quite some concerns on its profitability.
GLPG Financial Highlights
Over the last trailing twelve months GLPG reported a non-GAAP Earnings per Share(EPS) of 3.3. The EPS increased by 236.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 51.7% | ||
| ROA | 6.24% | ||
| ROE | 9.1% | ||
| Debt/Equity | 0 |
GLPG Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 52% to GLPG. The Buy consensus is the average rating of analysts ratings from 20 analysts.
For the next year, analysts expect an EPS growth of -140.29% and a revenue growth -46.03% for GLPG